Sold as Vesicare, Vesicare Ls. Every FDA application for this active ingredient: 2 branded and 26 generic.
As of Nov 16, 2026, FDA lists 28 applications for Solifenacin Succinate (sold as Vesicare, Vesicare Ls), first approved Nov 19, 2004, with 0 new uses approved and 1 published complete response letter.
| Solifenacin Succinate | Part D | $75.7M | +12% | 468,890 |
| Vesicare | Part D | $3.1M | -21% | 1,046 |
| Vesicare Ls | Part D | $32K | -6% | 38 |
| Nov 19, 2004 | VesicareNDA 21518 · New molecular entity | Astellas | 15 | Discontinued |
| Apr 2, 2014 | Solifenacin SuccinateANDA 91464 | Teva Pharms USA | 2 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 202551 | Watson Labs Inc | 1 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 205483 | Ajanta Pharma Ltd | 1 | Discontinued |
| May 20, 2019 | Solifenacin SuccinateANDA 205575 | Alembic | 1 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 209239 | Glenmark Speclt | 1 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 209333 | Qilu | 1 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 209719 | Amneal Pharms Co | 1 | Discontinued |
| May 20, 2019 | Solifenacin SuccinateANDA 209818 | Breckenridge | 0 | Discontinued |
| May 20, 2019 | Solifenacin SuccinateANDA 209839 | Cipla | 1 | Discontinued |
| May 20, 2019 | Solifenacin SuccinateANDA 210224 | Alkem Labs Ltd | 1 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 210281 | Bostal | 1 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 210582 | Chartwell Rx | 1 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 210688 | Msn | 2 | Marketed |
| May 20, 2019 | Solifenacin SuccinateANDA 211657 | Sciegen Pharms | 1 | Marketed |
| Aug 27, 2019 | Solifenacin SuccinateANDA 211701 | Unichem | 1 | Marketed |
| Sep 26, 2019 | Solifenacin SuccinateANDA 212214 | Novitium Pharma | 1 | Marketed |
| Dec 11, 2019 | Solifenacin SuccinateANDA 211423 | Rising | 1 | Marketed |
| Apr 13, 2020 | Solifenacin SuccinateANDA 213346 | Sunshine | 0 | Marketed |
| May 26, 2020 | Vesicare LsNDA 209529 · New dosage form | Astellas | 0 | Discontinued |
| Oct 19, 2020 | Solifenacin SuccinateANDA 207721 | Zydus Pharms | 0 | Discontinued |
| Jan 4, 2022 | Solifenacin SuccinateANDA 207477 | Accord Hlthcare | 0 | Discontinued |
| Jun 15, 2022 | Solifenacin SuccinateANDA 215761 | Annora Pharma | 0 | Marketed |
| Dec 27, 2022 | Solifenacin SuccinateANDA 206817 | Aurobindo Pharma | 0 | Marketed |
| Jun 6, 2023 | Solifenacin SuccinateANDA 211622 | Lannett Co Inc | 0 | Discontinued |
| Feb 20, 2024 | Solifenacin SuccinateANDA 204374 | Macleods Pharms | 0 | Marketed |
| Oct 2, 2024 | Solifenacin SuccinateANDA 205484 | Jubilant Generics | 0 | Marketed |
| Mar 4, 2025 | Solifenacin SuccinateANDA 209424 | Torrent | 0 | Discontinued |
| Letter | Product | Now |
|---|---|---|
| Aug 28, 2017 | Solifenacin succinateCarton And Co, Er Labeling, Facility Inspections | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA